open access

Vol 90, No 12 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-12-31
Get Citation

The prognostic significance of serum CA125 levels with ER, PR, P53 and Ki-67 expression in endometrial carcinomas

Emine Budak, Dudu Solakoglu Kahraman, Adnan Budak, Ahmet Yanarateş, Abdurrahman Hamdi Inan, Ahkam Göksel Kanmaz, Emrah Beyan
DOI: 10.5603/GP.2019.0116
·
Pubmed: 31909459
·
Ginekol Pol 2019;90(12):675-683.

open access

Vol 90, No 12 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-12-31

Abstract

Objectives: The present study evaluates the relationship between the expression levels of hormone receptors (HRs), Ki-67, p53 and serum cancer antigen 125 (CA125) levels in endometrial cancer and clinicopathological risk factors, and determines their prognostic values. Material and methods: This retrospective study included 49 patients with endometrial cancer whose estrogen receptor (ER) and progesterone receptor (PR) Ki-67 and p53 expression levels were determined through immunohistochemical methods, and whose preoperative serum CA125 levels were measured. These factors relationship with various clinicopathological factors, progression-free survival (PFS) and overall survival (OS) was investigated. Results: The study included 49 patients with EC with a mean age of 61 ± 10 years. The rate of HR positivity was significantly higher in the endometrioid histology group than in the non-endometroid histology group (p = 0.026). A high level of Ki- 67 expression was found to be associated with a non-endometroid histology (p = 0.016), and a high tumor grade (p < 0.001) and a high p53 expression were found to be associated with advanced disease stage (p = 0.026). A positive correlation was found between p53 and Ki-67, a negative correlation was found between p53 and Ki-67 and the presence of HR. Significant relationship was not found between HR status, p53, Ki-67, CA125 and either other clinicopathological risk factors or survival. Conclusions: While HR positivity indicates favorable clinicopathological prognostic factors, high Ki-67 and high p53 expression indicate unfavorable ones. However, no direct effect of these factors on prognosis was found in this study.

Abstract

Objectives: The present study evaluates the relationship between the expression levels of hormone receptors (HRs), Ki-67, p53 and serum cancer antigen 125 (CA125) levels in endometrial cancer and clinicopathological risk factors, and determines their prognostic values. Material and methods: This retrospective study included 49 patients with endometrial cancer whose estrogen receptor (ER) and progesterone receptor (PR) Ki-67 and p53 expression levels were determined through immunohistochemical methods, and whose preoperative serum CA125 levels were measured. These factors relationship with various clinicopathological factors, progression-free survival (PFS) and overall survival (OS) was investigated. Results: The study included 49 patients with EC with a mean age of 61 ± 10 years. The rate of HR positivity was significantly higher in the endometrioid histology group than in the non-endometroid histology group (p = 0.026). A high level of Ki- 67 expression was found to be associated with a non-endometroid histology (p = 0.016), and a high tumor grade (p < 0.001) and a high p53 expression were found to be associated with advanced disease stage (p = 0.026). A positive correlation was found between p53 and Ki-67, a negative correlation was found between p53 and Ki-67 and the presence of HR. Significant relationship was not found between HR status, p53, Ki-67, CA125 and either other clinicopathological risk factors or survival. Conclusions: While HR positivity indicates favorable clinicopathological prognostic factors, high Ki-67 and high p53 expression indicate unfavorable ones. However, no direct effect of these factors on prognosis was found in this study.

Get Citation

Keywords

endometrial cancer; prognosis; hormone receptor; ki67; p53; CA125

About this article
Title

The prognostic significance of serum CA125 levels with ER, PR, P53 and Ki-67 expression in endometrial carcinomas

Journal

Ginekologia Polska

Issue

Vol 90, No 12 (2019)

Pages

675-683

Published online

2019-12-31

DOI

10.5603/GP.2019.0116

Pubmed

31909459

Bibliographic record

Ginekol Pol 2019;90(12):675-683.

Keywords

endometrial cancer
prognosis
hormone receptor
ki67
p53
CA125

Authors

Emine Budak
Dudu Solakoglu Kahraman
Adnan Budak
Ahmet Yanarateş
Abdurrahman Hamdi Inan
Ahkam Göksel Kanmaz
Emrah Beyan

References (21)
  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–E386.
  2. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(1): 16–41.
  3. Huvila J, Laajala TD, Edqvist PH, et al. Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma. Gynecol Oncol. 2018; 149(1): 173–180.
  4. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355(9213): 1404–1411.
  5. Zeimet AG, Reimer D, Huszar M, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013; 105(15): 1142–1150.
  6. Lee SI, Catalano OA, Dehdashti F. Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET/CT, and PET/MR imaging. J Nucl Med. 2015; 56(3): 436–443.
  7. Burke WM, Orr J, Leitao M, et al. SGO Clinical Practice Endometrial Cancer Working Group, Society of Gynecologic Oncology Clinical Practice Committee, SGO Clinical Practice Endometrial Cancer Working Group, Society of Gynecologic Oncology Clinical Practice Committee. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014; 134(2): 385–392.
  8. Canlorbe G, Laas E, Bendifallah S, et al. Contribution of immunohistochemical profile in assessing histological grade of endometrial cancer. Anticancer Res. 2013; 33(5): 2191–2198.
  9. Yang B, Shan B, Xue X, et al. Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models. PLoS One. 2016; 11(5): e0155145.
  10. Solmaz U, Ekin A, Mat E, et al. Current management for endometrial cancer. Türk jinek onkol. 2016; 1: 7–16.
  11. Sivridis E, Giatromanolaki A, Koukourakis M, et al. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch. 2001; 438(5): 470–477.
  12. Liao BS, Twiggs LB, Leung BS, et al. Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma. Obstet Gynecol. 1986; 67(4): 463–467.
  13. Guan J, Xie L, Luo X, et al. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. J Gynecol Oncol. 2019; 30(1): e13.
  14. Köbel M, Atenafu EG, Rambau PF, et al. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. Gynecol Oncol. 2016; 141(3): 559–563.
  15. Nielsen AL, Nyholm HC. Proliferative activity as revealed by Ki-67 in uterine adenocarcinoma of endometrioid type: comparison of tumours from patients with and without previous oestrogen therapy. J Pathol. 1993; 171(3): 199–205.
  16. Marková I, Pilka R, Dusková M, et al. Selected immunohistochemical prognostic factors in endometrial cancer. Int J Gynecol Cancer. 2010; 20(4): 576–582.
  17. Di Donato V, Iacobelli V, Schiavi MC, et al. Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer. Int J Gynecol Cancer. 2018; 28(3): 505–513.
  18. Stefansson IM, Salvesen HB, Immervoll H, et al. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology. 2004; 44(5): 472–479.
  19. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol. 1999; 17(5): 1382–1390.
  20. Engelsen IB, Stefansson IM, Akslen LA, et al. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol. 2006; 195(4): 979–986.
  21. Yamauchi N, Sakamoto A, Uozaki H, et al. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol. 1996; 15(3): 202–208.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl